Rebate Model Cash-Flow Calculator
If a rebate model applies to drugs you purchase, the 340B discount no longer arrives at the point of purchase. Model working capital tied up while you pay upfront and wait for the rebate, using your own numbers.
- Browser tool
- Nothing stored
- Directional estimate
The discount moves from the point of purchase to a later claim.
Under a rebate approach, a covered entity pays a higher price upfront and later submits claims data to receive the difference as a rebate. Until that rebate is paid, the receivable ties up working capital.
For high-cost drugs and thin operating margins, the timing gap can affect budgets, reserves and borrowing. Denials, data errors and administration may add further costs not modeled here.
Enter your own numbers.
Estimate the rebate receivable and its carrying cost. A directional estimate only; see the disclaimer below the results.
Estimated working-capital exposure
$28,125
Cash tied up between purchase and rebate receipt, at any given time.
Annualized affected purchase volume
$900,000
Purchases across a full year that would move through the rebate model.
Estimated annual carrying cost
$2,250
Estimated financing cost of the working-capital exposure at your annual cost of capital.
This estimator is directional only and built from your inputs; nothing is stored or sent. It is not financial or legal advice. A real figure requires your actual claims and purchasing data.
Four steps to readiness
Identify affected drugs
Map which drugs and manufacturers fall under a rebate approach and how much of your spend they represent.
Quantify the cash gap
Model working capital tied up and carrying cost by month and site.
Prepare your data
Confirm claims data is complete and accurate enough to support rebate requests without preventable denials.
Plan for reconciliation
Track submitted claims, rebates received, denials and disputes.
Questions about rebate cash flow
What is the 340B rebate model?
Under a rebate approach, a covered entity pays a higher price upfront and later seeks the difference between that price and the 340B price after submitting required claims data.
Is a 340B rebate model currently in effect?
The scope and legal status of rebate programs can change. Check current HRSA guidance and consult qualified counsel before making operational decisions.
How can a rebate model affect covered entities?
Potential impacts include working capital tied up while rebates are pending, added claims-data administration, and delayed or denied rebates.